What is KPV?
A tripeptide, lysine–proline–valine (Lys-Pro-Val), that the FDA describes as a fragment of alpha-melanocyte-stimulating hormone (α-MSH), a pituitary neuropeptide.
US legal status
Open question
HHS's KPV policy is still a "draft", and we found no final version. For oral products the policy requires documented oral bioavailability in people, and we found no such human data for KPV, so whether any oral KPV can meet that condition is not settled.
Changes
What the human evidence looks like
Safety facts
Reports to the FDA
What the FDA has said
- The FDA's Category 2 page says the FDA "has not identified any human exposure data" for KPV and lacks information on whether it "would cause harm".5
- The FDA's briefing calls both forms "not well-characterized": there is no standard naming and no published impurity, aggregate or microbiological testing, and the nominator supplied no certificate of analysis.6
- The FDA said there are not enough data to conclude that KPV does not carry immunogenicity or aggregation risks, and that peptides as short as 2 amino acids can aggregate.6
No data
- The FDA found no nonclinical toxicity studies of topical KPV. We found no carcinogenicity, reproductive or liver data in any source we read.6
- We found no human data, no FAERS report and no FDA statement about KPV and the liver.
- We found no human study of how the body handles KPV (pharmacokinetics) by any route, and no published human half-life.6
- There are no data for any group: not for pregnancy, breastfeeding, children or long-term use, and not for any route.6
Compounded KPV is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
The conditions of the HHS policy
The policy covers a compounded product only when all of its conditions are met.
- 1.HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (10 conditions, Appendix A)Tier 1: regulator or registerHHSread Nov 16, 2026↩
- 2.Appendix B: Peptide Identities and JustificationsTier 1: regulator or registerHHSread Nov 16, 2026↩
- 3.Federal Register notice FR Doc 2026-22192, 91 FR 68526 (Oct 30, 2026)Tier 1: regulator or registerFederal Registerread Nov 16, 2026↩
- 4.Docket HHS-OASH-2026-0496Tier 1: regulator or registerRegulations.govread Nov 16, 2026↩
- 5.Certain bulk drug substances that may present significant safety risks (Apr 22, 2026)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 6.FDA Briefing Document: KPV-related bulk drug substances, PCAC July 23–24, 2026Tier 1: regulator or registerFDA CDERread Nov 16, 2026↩
- 7.PCAC questions, July 23–24, 2026Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 8.PCAC meeting page, July 23–24, 2026 (no minutes)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 9.Bulk-list bound? PCAC backs majority of peptides (Jul 27, 2026)Tier 3: reference, law firm or pressMcDermott Will & Schulteread Nov 16, 2026↩
- 10.WADA Prohibited List 2026Tier 1: regulator or registerWADAread Nov 16, 2026↩
- 11.USADA sanctions tableTier 1: regulator or registerUSADAread Nov 16, 2026↩
- 12.openFDA FAERS, medicinalproduct KPV (0; data to 2026-10-28)Tier 1: regulator or registeropenFDAread Nov 16, 2026↩
- 13.openFDA Drugs@FDA, active ingredient KPV (no match)Tier 1: regulator or registeropenFDAread Nov 16, 2026↩
- 14.eCFR 21 CFR Part 1308 (2026-11-01)Tier 1: regulator or registerOffice of the Federal Registerread Nov 16, 2026↩
- 15.ClinicalTrials.gov API, query.intr=KPV (0 studies)Tier 1: regulator or registerNIH NLMread Nov 16, 2026
- 16.PubMed E-utilities counts for KPV (queries in 3)Tier 1: regulator or registerNIH NLMread Nov 16, 2026
- 17.Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134(1):166-78. PMID 18061177Tier 2: peer-reviewed or trial registryElsevier / AGAread Nov 16, 2026
- 18.Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing. Exp Eye Res 2006. PMID 16965771Tier 2: peer-reviewed or trial registryElsevierread Nov 16, 2026
- 19.Conformational analysis of tripeptide Ac-Lys-Pro-Val-NH2, COOH-terminal sequence of alpha-MSH. J Pharm Pharmacol 2001. PMID 11480545Tier 2: peer-reviewed or trial registryWileyread Nov 16, 2026
- 20.Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008. PMID 18092346Tier 2: peer-reviewed or trial registryWileyread Nov 16, 2026
- 21.Viennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016;2(3):340-357. PMID 27458604Tier 2: peer-reviewed or trial registryElsevierread Nov 16, 2026
- 22.Xiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles. Mol Ther 2017;25(7):1628-1640. PMID 28143741Tier 2: peer-reviewed or trial registryCell Pressread Nov 16, 2026
- 23.Pawar K et al. Transdermal iontophoretic delivery of KPV across microporated human skin. J Pharm Sci 2017;106(7):1814-1820. PMID 28343991Tier 2: peer-reviewed or trial registryElsevier / APhAread Nov 16, 2026
- 24.Compounding and the FDA: questions and answersTier 1: regulator or registerFDAread Nov 16, 2026
- 25.Federal Register API document searches: "KPV", and peptide compounding documents since Oct 30, 2026Tier 1: regulator or registerFederal Registerread Nov 16, 2026↩
- 26.Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Updated May 14, 2026)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 27.Warning letter: Peak Performance Peptides, MARCS-CMS 735127 (Aug 24, 2026), KPV not namedTier 1: regulator or registerFDAread Nov 16, 2026↩
- 28.Warning letter: Peptide Partners LLC, MARCS-CMS 735063 (Aug 24, 2026), KPV not namedTier 1: regulator or registerFDAread Nov 16, 2026↩
- 29.Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (Updated March 21, 2025)Tier 1: regulator or registerFDAread Nov 16, 2026↩
We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.